Clinical trial
EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
NCT00916474 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- December 31, 2013
- Enrollment
- 408 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.